We hold worldwide commercialization rights to pimavanserin. Currently, there are no approved medicines for the treatment of Rett syndrome. Our PDUFA target action date is April 3, 2021. Two of four commitments are already completed within the agreed upon timelines. Discontinuations due to adverse events were 2.9% for pimavanserin and 3.6% for placebo. The sNDA is supported by results from the pivotal Phase 3 HARMONY study. Our failure to compete effectively could have a material adverse effect on our business. These patent terms include adjustments made by the PTO, but not extensions. Coverage policies and third-party payor reimbursement rates may change at any time. We added 98 new employees in 2020. Employee Engagement, Benefits & Development. We initiated the Phase 3 LAVENDER study of trofinetide for Rett syndrome in October 2019. Additionally, NUPLAZID is still subject to substantial, ongoing regulatory requirements. There is no guarantee that future studies with pimavanserin will be successful. As of December 31, 2020, we employed approximately 600 employees. This could have a material adverse effect on our ability to access sufficient funding. On December 10, 2020, we filed our answer to MSN's counterclaims. It is difficult to determine how such disputes would be resolved. As a result, we may be subject to criminal and civil liability. Even successful defense would require significant financial and management resources. Defendants filed a motion to dismiss the consolidated complaint on June 7, 2019. Lead plaintiff opposed the motion on September 15, 2020. 20-cv-0843) was filed in the U.S. District Court for the District of Delaware.
